GlassScriptPhysician profile
Mary A Ward
NPI 1821278813
$1,723.37
in general payments reported to CMS, 2019-2025
18 companies · $443 in 2025
The $443 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $262 · 2022: $494 · 2023: $226 · 2024: $298 · 2025: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $967.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $292.13 | 2021-2025 | Wegovy, Rybelsus, Saxenda |
| Abbvie INC. | $284.89 | 2022-2024 | |
| Abbott Laboratories | $189.10 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Lilly USA, LLC | $171.50 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $157.23 | 2022-2025 | Evenity, Prolia, Otezla |
| Corcept Therapeutics | $140.56 | 2024-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $133.60 | 2022-2025 | |
| Tandem Diabetes Care, INC. | $70.09 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.58 | 2021-2025 | Jardiance |
| Averitas Pharma INC. | $36.97 | 2025 | Qutenza |
| Astrazeneca Pharmaceuticals LP | $30.05 | 2025 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.85 | 2022 | |
| Glaxosmithkline, LLC. | $27.47 | 2022 | |
| Insulet Corporation | $26.41 | 2024 | Omnipod |
| Daiichi Sankyo INC. | $24.88 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $18.75 | 2025 | Twiist |
| Madrigal Pharmaceuticals | $17.54 | 2025 | Rezdiffra |
| Ibsa Pharma INC. | $14.77 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.